Semaglutide (Credit: Canva)
Until now, Ozempic has only been linked to mild side effects like nausea, indigestion etc but recent research has linked it to a life-threatening consequence. A new study by scientists from the University of Alberta suggests that weight loss medications like semaglutide, marketed as Ozempic and Wegrovy, may shrink heart muscle in addition to reducing body weight. Their findings showed that semaglutide reduced heart muscle mass in both lean and obese mice, as well as in lab-grown human heart cells. It was published in JACC: Basic to Translational Science.
In the study, mice on a high-fat, high-sucrose diet were transitioned to a standard diet, simulating reduced calorie intake. After three weeks of semaglutide treatment, the mice lost around 30% of their body weight and 65% of their fat mass. However, their hearts showed signs of muscle loss, particularly in the left ventricles, the heart's main pumping chamber. Despite the reduction in heart mass, the heart's ability to pump blood and relax between beats remained unaffected. Lean mice also experienced muscle loss, losing 8.2% of their skeletal muscle mass without significant changes in body weight or heart function.
While clinical studies suggest that side effects are generally similar across sexes, some evidence points to a higher prevalence of certain reactions in women as compared to men.
Ozempic belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. Commonly reported side effects include nausea, vomiting, diarrhoea, fatigue, and abdominal pain. A 2022 study involving semaglutide found that 36.6% of participants experienced nausea and vomiting, while 8.6% reported diarrhoea. Notably, a majority (75%) of participants in this study were female, highlighting the importance of examining gender-related differences in drug reactions.
ALSO READ: Does Ozempic Have Different Side Effects On Women And Men?
© 2024 Bennett, Coleman & Company Limited